Literature DB >> 12077291

Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-kappa B expression and binding to the IL-12 p40 promoter.

Jiajian Liu1, David Beller.   

Abstract

Intrinsic defects in macrophage (M(phi)) cytokine production characterize many autoimmune-prone mouse strains. Aberrant levels of IL-12, for example, are produced by M(phi) isolated from young mice prone to lupus (MRL and NZB/W) and diabetes (nonobese diabetic (NOD)) well before the appearance of disease signs. Evaluation of the possible mechanism(s) underlying the abnormal regulation of IL-12 in these strains revealed novel patterns of Rel family protein binding to the unique p40 NF-kappaB site in the IL-12 p40 promoter, whereas binding patterns to Ets and CCAAT enhancer binding protein/beta sites were normal. In particular, the heightened production of IL-12 by NOD M(phi) is associated with elevated levels of the trans-activating p50/c-Rel (p65) complex compared with the nonfunctional p50/p50 dimer. Conversely, the dramatically impaired production of IL-12 by both NZB/W and MRL/+ M(phi) is associated with a predominance of p50/p50 and reduced p50/c-Rel(p65) binding. Mechanistically, the unique pattern seen in the lupus strains reflects elevated p50 and reduced c-Rel nuclear protein levels. In NOD extracts, the level of c-Rel is elevated compared with that in lupus strains, but not when compared with that in normal A/J. However, the extent of c-Rel tyrosine phosphorylation noted in NOD extracts is more than double that seen in any other strain. Levels of p65 were similar in all strains tested. These findings reveal that a common mechanism, involving dysregulation of c-Rel and p50, may be used to determine the aberrant IL-12 levels that have the potential to predispose specific mouse strains to systemic or organ-specific autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077291     DOI: 10.4049/jimmunol.169.1.581

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Dendritic cells, T cell tolerance and therapy of adverse immune reactions.

Authors:  P A Morel; M Feili-Hariri; P T Coates; A W Thomson
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 2.  Dendritic cell immunotherapy for autoimmune diabetes.

Authors:  Maryam Feili-Hariri; Rafael R Flores; A Cecilia Vasquez; Penelope A Morel
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  Dendritic cells from lupus-prone mice are defective in repressing immunoglobulin secretion.

Authors:  Mileka R Gilbert; Diane G Carnathan; Patricia C Cogswell; Li Lin; Albert S Baldwin; Barbara J Vilen
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

4.  Pancreatic islet expression of chemokine CCL2 suppresses autoimmune diabetes via tolerogenic CD11c+ CD11b+ dendritic cells.

Authors:  Martin A Kriegel; Chozhavendan Rathinam; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-10       Impact factor: 11.205

5.  TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production.

Authors:  Petar Lenert; Rachel Brummel; Elizabeth H Field; Robert F Ashman
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

6.  Cytokine-induced monocyte characteristics in SLE.

Authors:  Zhe Zhang; Kelly Maurer; Juan C Perin; Li Song; Kathleen E Sullivan
Journal:  J Biomed Biotechnol       Date:  2010-06-24

Review 7.  Autologous umbilical cord blood infusion for type 1 diabetes.

Authors:  Michael J Haller; Hilla-Lee Viener; Clive Wasserfall; Todd Brusko; Mark A Atkinson; Desmond A Schatz
Journal:  Exp Hematol       Date:  2008-03-20       Impact factor: 3.084

8.  Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents.

Authors:  C Gysemans; K Stoffels; A Giulietti; L Overbergh; M Waer; M Lannoo; U Feige; C Mathieu
Journal:  Diabetologia       Date:  2003-07-17       Impact factor: 10.122

9.  M-CSF cooperating with NFκB induces macrophage transformation from M1 to M2 by upregulating c-Jun.

Authors:  Yujiao Yang; Junfang Qin; Lan Lan; Ning Li; Chengfang Wang; Pengfei He; Fang Liu; Hong Ni; Yue Wang
Journal:  Cancer Biol Ther       Date:  2013-10-22       Impact factor: 4.742

10.  A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner.

Authors:  Yupin Charoenvit; Gary T Brice; David Bacon; Victoria Majam; Jackie Williams; Esteban Abot; Harini Ganeshan; Martha Sedegah; Denise L Doolan; Daniel J Carucci; Daniel H Zimmerman
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.